Skip to Main Content

Paper Details

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Neuro Oncol
29
2023
HER, HER-2, HER-2 Positive Cancer, HER-positive, HER2, HER2 receptor, HER2-positive breast cancer, LMD, Leptomeningeal Metastases, Patients, Trastuzumab, arachnoiditis, human epidermal growth factor receptor 2, human epidermal growth factor receptor 2-positive (HER2-positive) cancers, patients, trastuzumab
Author NameAffiliation
Priya KumthekarDepartment of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Nancy U LinDana-Farber Cancer Institute Harvard Medical School
Morris D Groves
  • 1 - 3

Datasets

Release 1.2